XML 238 R91.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies (Details)
3 Months Ended 12 Months Ended
May 23, 2023
shares
Oct. 25, 2017
USD ($)
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2025
CNY (¥)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
CNY (¥)
Dec. 31, 2023
USD ($)
Apr. 06, 2022
Commitments and Contingencies [Line Items]                  
Cash payment     $ 1,369,586     $ 2,856,309   $ 285,400  
Loans payable   $ 100,000              
Shares of common stock (in Shares) | shares 5,000                
Litigation amount     $ 450,000     $ 450,000      
Percentage of pre-tax profit     30.00% 30.00%   30.00% 30.00%    
Pre-tax profit     $ 3,333,333     $ 3,333,333      
Payment for rent     32,000   $ 32,000 127,000   $ 129,000  
Cash services     10,000,000     10,000,000      
Working capital     $ 700,000 ¥ 5,000,000   $ 700,000 ¥ 5,000,000    
Dr. Zhou [Member]                  
Commitments and Contingencies [Line Items]                  
Cash payment   876,087              
Percentage of pre-tax profit     20.00% 20.00%   20.00% 20.00%    
Consideration amount   876,087              
Settled Litigation [Member]                  
Commitments and Contingencies [Line Items]                  
Cash payment   450,000              
Litigation amount     $ 373,450   $ 373,450 $ 373,450      
Percentage of pre-tax profit     10.00% 10.00%   10.00% 10.00%    
Pre-tax profit     $ 3,333,333     $ 3,333,333      
Consideration amount   $ 450,000              
Common Stock [Member] | Dr. Zhou [Member]                  
Commitments and Contingencies [Line Items]                  
Shares of common stock (in Shares) | shares   400              
Common Stock [Member] | Settled Litigation [Member]                  
Commitments and Contingencies [Line Items]                  
Shares of common stock (in Shares) | shares   3,333              
Avactis Biotherapeutics Limited [Member]                  
Commitments and Contingencies [Line Items]                  
Ownership percentage                 60.00%
Arbele Biotherapeutics [Member]                  
Commitments and Contingencies [Line Items]                  
Ownership percentage                 40.00%
Contribution amount     $ 6,660,000     $ 6,660,000      
Avactis Nanjing Biosciences Ltd. [Member]                  
Commitments and Contingencies [Line Items]                  
Ownership percentage                 100.00%